LCP2

Chr 5q35.1

lymphocyte cytosolic protein 2

Aliases:: SLP-76
MANE:: ENST00000046794.10

OMIM: 601603 ↗NCBI: 3937 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

LCP2 · Q13094

v62025-08-01

Predicted Aligned Error matrix for LCP2 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

62.9/ 100

Low

533 residues

Confidence breakdown

Very high(≥ 90)20%
Confident(70–90)14%
Low(50–70)24%
Very low(< 50)41%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

Primary immunodeficiency or monogenic inflammatory bowel disease
BIALLELIC, autosomal or pseudoautosomal

Disease associations (Open Targets)

immunodeficiency 81
0.52
cardiomyopathy
0.28
glomerulonephritis
0.25
ovarian dysfunction
0.25
neurodegenerative disease
0.24
early-onset non-syndromic cataract
0.11
Total congenital cataract
0.11
Posterior polar cataract
0.11
early-onset zonular cataract
0.10
Partial congenital cataract
0.10

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Lymphocyte cytosolic protein 2

Adapter protein primarily involved in signaling pathways within T-cells, as well as other immune cells such as platelets, mast cells, and natural killer (NK) cells (PubMed:11313406, PubMed:33159816). Plays a crucial role for transducing signal from the T-cell receptor (TCR) after antigen recognition leading to T-cell activation. Mechanistically, once phosphorylated by the kinase ZAP70, mediates interactions with the guanine-nucleotide exchange factor VAV1, the adapter protein NCK and the kinase ITK (PubMed:8673706, PubMed:8702662). In turn, stimulates the activation of PKC-theta/PRKCQ and NF-kappa-B transcriptional activity in response to CD3 and CD28 costimulation (PubMed:11313406). Also plays an essential role in AGER-induced signaling pathways including p38 MAPK and ERK1/2 activation leading to cytokine release and pro-inflammatory responses (PubMed:33436632)